[Ulcerative colitis in children. Levels of salicylazosulfapyridine and sulfapyridine during treatment]. / Colitis ulcerosa en niños. Niveles de salazosulfapiridina y sulfapiridina durante el tratamiento.

Salicylazosulfapyridine (SASP) is a drug used in the treatment of ulcerative colitis (UC) owing to the therapeutic action of the 5-aminosalicylic acid produced by the splitting of the molecule in the cecum, which also yields the absorbable compound Sulphapyridine (SP). The aim of our work was to assess the levels of the drug in blood (SASP and SP), to correlate them with undesirable effects in any, to verify their fluctuations in the dosing interval and to investigate the extent of the excretion of the drug in the children who were studied. 10 children (6 to 16 years) with UC, who were treated with SASP (dOsage schedule 0.5-2.0 g/day in a 12 hours interval), were studied. Blood levels of SASP and SP were assessed at 6 and 12 hours after doses, and total fecal excretion of SASP was determines in 24 hs specimens. All the determinations were performed according to Hansson and Sandberg. SP plasma levels were 17.7 +/- 9.0 ug/ml (range 6.8-36.3 ug/ml) at 6 hours after doses. and 14.1 +/- 7.2 ug/ml (range 5.7-25.0 ug/ml) at 12 hours after doses. SASP plasma levels were 15.5 +/- 15.4 ug/ml (range 2.1-53.4 ug/ml) at 6 hours after doses, and 14.0 +/- 20.4 ug/ml (range 3.9-70.7 ug/ml) at 12 hours after doses. The 24 hours fecal excretion was 17.4 to 236 mg. These values were correlated with the given doses (r = 0.88) calculated as SASP g/m2 body surface 24 hs. There was no statistical correlation between doses and SP or SASP levels in this group, and the respective levels of SASP and SP at 6 and 12 hours after doses showed no significative differences.(ABSTRACT TRUNCATED AT 250 WORDS)

Colitis ulcerosa en niños. Niveles de salazosulfapiridina y sulfapiridina durante el tratamiento. / [Ulcerative colitis in children. Levels of salicylazosulfapyridine and sulfapyridine during treatment]

Salicylazosulfapyridine (SASP) is a drug used in the treatment of ulcerative colitis (UC) owing to the therapeutic action of the 5-aminosalicylic acid produced by the splitting of the molecule in the cecum, which also yields the absorbable compound Sulphapyridine (SP). The aim of our work was to assess the levels of the drug in blood (SASP and SP), to correlate them with undesirable effects in any, to verify their fluctuations in the dosing interval and to investigate the extent of the excretion of the drug in the children who were studied. 10 children (6 to 16 years) with UC, who were treated with SASP (dOsage schedule 0.5-2.0 g/day in a 12 hours interval), were studied. Blood levels of SASP and SP were assessed at 6 and 12 hours after doses, and total fecal excretion of SASP was determines in 24 hs specimens. All the determinations were performed according to Hansson and Sandberg. SP plasma levels were 17.7 +/- 9.0 ug/ml (range 6.8-36.3 ug/ml) at 6 hours after doses. and 14.1 +/- 7.2 ug/ml (range 5.7-25.0 ug/ml) at 12 hours after doses. SASP plasma levels were 15.5 +/- 15.4 ug/ml (range 2.1-53.4 ug/ml) at 6 hours after doses, and 14.0 +/- 20.4 ug/ml (range 3.9-70.7 ug/ml) at 12 hours after doses. The 24 hours fecal excretion was 17.4 to 236 mg. These values were correlated with the given doses (r = 0.88) calculated as SASP g/m2 body surface 24 hs. There was no statistical correlation between doses and SP or SASP levels in this group, and the respective levels of SASP and SP at 6 and 12 hours after doses showed no significative differences.(ABSTRACT TRUNCATED AT 250 WORDS)

[Fecal alpha 1-antitrypsin clearance in protein-losing enteropathies in pediatrics]. / Clearance fecal de alfa-1-antitripsina en enteropatías perdedoras de proteínas en pediatría.

Fecal alpha-1-antitrypsin clearance (A-1-At Cl) was performed on 47 pediatric age patients with various digestive diseases: 6 with ulcerative colitis, 5 with celiac disease, 6 with cow milk protein intolerance, 1 with intestinal lymphangiectasia, 1 with non specific diarrhea and the control group was composed of 10 children without digestive disease. The group of patients with digestive disease showed values of fecal A-1-At Cl significantly higher than the control and non specific diarrhea groups (p less than 0.05). Just 1 child with cow milk intolerance had A-1-At Cl within the range of values of the control group x = 2 S.D. All children with non specific diarrhea excepting one had values falling within the control range. The patient with thalassemia major had a very elevated value of A-1-At Cl. The cause of this finding remains unknown at present. The fecal A-1-At Cl. is a non invasive, cost saving, useful and simpler method than the traditional techniques for the diagnosis of protein losing enteropathy in childhood.

Clearance fecal de alfa-1-antitripsina en enteropatías perdedoras de proteínas en pediatría. / [Fecal alpha 1-antitrypsin clearance in protein-losing enteropathies in pediatrics]

Fecal alpha-1-antitrypsin clearance (A-1-At Cl) was performed on 47 pediatric age patients with various digestive diseases: 6 with ulcerative colitis, 5 with celiac disease, 6 with cow milk protein intolerance, 1 with intestinal lymphangiectasia, 1 with non specific diarrhea and the control group was composed of 10 children without digestive disease. The group of patients with digestive disease showed values of fecal A-1-At Cl significantly higher than the control and non specific diarrhea groups (p less than 0.05). Just 1 child with cow milk intolerance had A-1-At Cl within the range of values of the control group x = 2 S.D. All children with non specific diarrhea excepting one had values falling within the control range. The patient with thalassemia major had a very elevated value of A-1-At Cl. The cause of this finding remains unknown at present. The fecal A-1-At Cl. is a non invasive, cost saving, useful and simpler method than the traditional techniques for the diagnosis of protein losing enteropathy in childhood.

[Determination of amylase creatinine clearance in children and adolescents]. / Determinación de clearance de amilasa creatinina en niños y adolescentes.

UNLABELLED: 24 children whose ages ranged from 10 days to 14 years (x 5.5. ys.), 16 males and 8 females, hospitalized in our Service on account of extra-digestive were studied. Creatinine and amylase determination were performed on serum and 24 hs. urine specimens; lipase activity was measured only in serum. Amylase-creatinine clearance ratio varied between 1.3 and 5.8% (x 3.1 +/- 1.3). Serum amylase ranged from 36 to 460 U/l (x 123 U/l). Five patients had hyperamylasemia. 2 were urlian parotiditis, 2 were under clinical surveillance after surgery and the last one was a septic meningitis. All of them showed amylase-creatinine ratio values up to 2.5%. Serum lipase ranged from 6 to 197 U/l (x 79 U/l), falling into the normal interval. No abnormal clearance was found. CONCLUSIONS: hyperamylasemia is not specific for pancreatic disturbances in children; the serum lipase and the amylase-creatinine clearance ratio seem to be useful tools to rule out pancreatic involvement in hyperamylasemic patients.

Determinación de clearance de amilasa creatinina en niños y adolescentes. / [Determination of amylase creatinine clearance in children and adolescents]

24 children whose ages ranged from 10 days to 14 years (x 5.5. ys.), 16 males and 8 females, hospitalized in our Service on account of extra-digestive were studied. Creatinine and amylase determination were performed on serum and 24 hs. urine specimens; lipase activity was measured only in serum. Amylase-creatinine clearance ratio varied between 1.3 and 5.8

(x 3.1 +/- 1.3). Serum amylase ranged from 36 to 460 U/l (x 123 U/l). Five patients had hyperamylasemia. 2 were urlian parotiditis, 2 were under clinical surveillance after surgery and the last one was a septic meningitis. All of them showed amylase-creatinine ratio values up to 2.5

. Serum lipase ranged from 6 to 197 U/l (x 79 U/l), falling into the normal interval. No abnormal clearance was found. Conclusions: hyperamylasemia is not specific for pancreatic disturbances in children; the serum lipase and the amylase-creatinine clearance ratio seem to be useful tools to rule out pancreatic involvement in hyperamylasemic patients.

[Fibrocystic disease of the pancreas: a presentation feature. Anatomopathological report]. / Enfermedad fibroquística de páncreas: una forma de presentación. Descripción anatomopatológica.

Five patients with CF (cystic fibrosis) dead between 1974 to 1982 at ages ranging from one to six months are presented. All of them showed edema, hypoalbuminemia and anemia in a severely compromised clinical situation, and failure to gain weight in spite of being breast-fed in the first weeks of life, in four of them. All of them were second or third degree malnourished babies (Gomez classification) at admission. Five children presented edema, two severe, two moderate and one mild. Hematocrit values ranged from 19% to 39% (means 26.4%), and albuminemia from 1.60 to 3.00 g/% (means 2.14 g/%). Two patients presented antecedents of dead brothers. All of them received substitution therapy with pancreatic enzymes. The children dead within seven and seventeen days of admission (means ten days) of broncho-pulmonar disfunction. In this work, we wish to call the pediatrician's attention about the importance of making this diagnostic presumption in the first months of the life.